Prospective randomized study of sulindac versus calcium and calciferol for upper gastrointestinal polyps in familial adenomatous polyposis

Br J Surg. 1996 Dec;83(12):1763-6. doi: 10.1002/bjs.1800831232.

Abstract

Eighteen patients with familial adenomatous polyposis (FAP) who had previously undergone colectomy but had upper gastrointestinal polyps were studied in a double-blind randomized crossover trial comparing sulindac with calcium and calciferol. Sulindac produced a reduction in the crypt proliferation index in the gastric epithelium of patients but did not significantly affect duodenal mucosa. Calcium with calciferol did not have any effects on crypt proliferation index in patients with FAP.

Publication types

  • Clinical Trial
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adenomatous Polyposis Coli / drug therapy*
  • Adenomatous Polyposis Coli / pathology
  • Calcium / therapeutic use*
  • Cell Division
  • Common Bile Duct Neoplasms / drug therapy*
  • Common Bile Duct Neoplasms / pathology
  • Cross-Over Studies
  • Duodenal Neoplasms / drug therapy*
  • Duodenal Neoplasms / pathology
  • Ergocalciferols / therapeutic use*
  • Humans
  • Intestinal Polyps / drug therapy*
  • Intestinal Polyps / pathology
  • Prospective Studies
  • Stomach Neoplasms / drug therapy*
  • Stomach Neoplasms / pathology
  • Sulindac / therapeutic use*

Substances

  • Ergocalciferols
  • Sulindac
  • Calcium